Joint pain

Joint pain, clinically referred to as arthralgia, is a physical symptom characterized by discomfort, aching, or soreness in one or more joints of the body [1, 2]. It is not considered a molecular target, such as a receptor or enzyme; instead, it is a manifestation of various underlying pathological conditions, most notably osteoarthritis, rheumatoid arthritis, and gout [5, 7]. The biological experience of joint pain arises from the activation and sensitization of nociceptors by a cocktail of inflammatory mediators, including prostaglandins, bradykinin, and pro-inflammatory cytokines like TNF-alpha and IL-6 [10, 12]. In drug development, 'joint pain' is frequently used as a primary clinical endpoint rather than a target for drug binding. Therapeutic strategies focus on modulating specific molecular targets within the pain and inflammatory pathways, such as cyclooxygenase (COX) enzymes, nerve growth factor (NGF), and transient receptor potential (TRP) ion channels, to alleviate the symptom [11, 14, 15]. For biotech analysts, distinguishing between the clinical indication (joint pain) and the underlying molecular targets is critical for evaluating therapeutic efficacy and mechanism of action.

Other names

ArthralgiaArticular painJoint acheJoint soreness

Joint pain is a clinical symptom, not a molecular target. Drugs used to treat joint pain operate by inhibiting specific molecular targets such as cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, or by neutralizing cytokines like tumor necrosis factor (TNF) and interleukin-1 (IL-1) to suppress inflammation [10, 12]. Other mechanisms include the antagonism of receptors involved in pain signaling, such as the nerve growth factor (NGF) receptor (TrkA) or transient receptor potential (TRP) ion channels [14, 15].